A Phase 1b/2 Open-Label Study of APVO436 in Combination With Venetoclax and Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Latest Information Update: 19 May 2025
At a glance
- Drugs Azacitidine (Primary) ; Mipletamig (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Acronyms RAINIER
- Sponsors Aptevo Therapeutics
Most Recent Events
- 14 Feb 2025 According to Aptevo Therapeutics Media Release, the Company anticipates providing multiple data readouts in 2025 and to present results at the American Society of Hematology meeting in the fourth quarter.
- 14 Feb 2025 Results presented in the Aptevo Therapeutics Media Release.
- 14 Feb 2025 Status changed from not yet recruiting to recruiting.